



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Tegatrabetan

Cat. No.:	HY-109103
CAS No.:	1227637-23-1
Molecular Formula:	C ₂₈ H ₃₆ N ₄ O ₆ S ₂
Molecular Weight:	588.74
Target:	β-catenin
Pathway:	Stem Cell/Wnt
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (84.93 mM; ultrasonic and warming and heat to 60°C)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		1.6985 mL	8.4927 mL	16.9854 mL
		5 mM		0.3397 mL	1.6985 mL	3.3971 mL
		10 mM		0.1699 mL	0.8493 mL	1.6985 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (4.25 mM); Suspended solution; Need ultrasonic					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (4.25 mM); Suspended solution; Need ultrasonic					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (4.25 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	Tegatrabetan (BC2059) is a β-Catenin antagonist. Tegatrabetan disrupts the binding of β-catenin with the scaffold protein transducin β-like 1 (TBL1) ^[1] .
IC ₅₀ & Target	β-Catenin ^[1]
In Vitro	Tegatrabetan (BC2059; 20-100 nM; 48 hours) inhibits cell proliferation in suspension culture over 120 hours and induces apoptosis of cultured human acute myeloid leukemia (AML) HL-60, OCI-AML3 and MV4-11 cells dose-dependently ^[1] .

?Tegatrabetan (20 and 50 nM; 24 hours) induces a modest but significant accumulation of cells in the G0/G1 phase, with a concomitant decline in the G2/M phase of the cell cycle^[1].
 ?Tegatrabetan (100 nM, 24 hours) depletes the levels of β -catenin and its target genes, including c-MYC and survivin without affecting the levels of the TBL1 in OCI-AML3, HL-60 and MV4-11 cells^[1].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.
 Cell Proliferation Assay^[1]

Cell Line:	HL-60, OCI-AML3 and MV4-11 cells
Concentration:	20, 50, and 100 nM
Incubation Time:	48 hours
Result:	Dose-dependently inhibited cell proliferation.

Cell Cycle Analysis^[1]

Cell Line:	OCI-AML3 cells
Concentration:	20 and 50 nM
Incubation Time:	24 hours
Result:	Dose-dependently induced cell cycle growth arrest.

Western Blot Analysis^[1]

Cell Line:	OCI-AML3, HL-60 and MV4-11 cells
Concentration:	100 nM
Incubation Time:	24 hours
Result:	Treatment depleted β -Catenin expression levels.

In Vivo

Tegatrabetan (BC2059; 1.0 or 5.0 mg/kg/day; intravenously) significantly improves the median survival of the mice from approximately 17.5 to 39 days. Treatment with Tegatrabetan (10 mg/kg/day; intravenously) alone further improves the median survival to 51.5 days^[1].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NOD/SCID mice bearing OCI-AML3 xenografts ^[1]
Dosage:	1 mg/kg; 5 mg/kg; 10 mg/kg
Administration:	Intravenously; 1 mg/kg daily 4 days per week or 5 mg/kg or 10 mg/kg of BC2059 twice per week (Tuesday and Thursday) for 3 weeks.
Result:	Treatment significantly improved survival of NOD/SCID mice bearing OCI-AML3 xenografts.

CUSTOMER VALIDATION

- Eur J Pharmacol. 2022 Apr 21;924:174940.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Fiskus W, et al. Pre-clinical efficacy of combined therapy with novel β -catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. Leukemia. 2015 Jun;29(6):1267-78.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA